Lightcast Discovery, a Cambridge, UK-based life science tools company developing a novel single-cell functional analysis platform, raised $49M in Series B funding.
The round was led by M Ventures with participation from ARCH Venture Partners, Illumina Ventures, OMX Ventures, +ND Capital and Longwall Ventures.
The company intends to use the funds to accelerate growth and expansion leading up to full commercial launch further enabled by appointment of CCO Paul Steinberg.
Led by CEO Paul Loeffen, Lightcast is advancing single-cell functional analysis with a flexible droplet-based platform that can load, select, process, analyze, and recover individual cells at the same time. This novel technology enables the manipulation of addressable picolitre droplets with light in a massively parallel manner, enabling sequential assays beyond transcriptome-only readouts. Its platform offers flexibility to analyze a wide range of cell types and assays, as well as the precision to meticulously control and monitor the number, occupancy, location, and movement of each droplet.
FinSMEs